Effectiveness of Antiviral Drugs as Covid-19 Therapy
DOI:
https://doi.org/10.30872/j.trop.pharm.chem.v5i3.218Keywords:
Covid-19, Sars-CoV-2, AntiviralAbstract
Introduction: SARS-CoV 2 firstly emerged in China on December 2019 and it was spreading rapidly across the world until now. At this time, there is no vaccine or medication approved by the FDA. However, there are some FDA approved medicines for treating other diseases that can be used for Covid-19 based on tests. This review focuses on therapy efficacy, work mechanism, pharmacokinetic profile, safety, and future perspective. Method: Article review related to therapy on Covid-19 patients, particularly antiviral therapy which was the combination of lopinavir and ritonavir, chloroquine, hydroxychloroquine, remdesivir, and favipiravir. The reviewed relevant articles were observational study, in vitro test, case report, and clinical test. Results: A total of 13 articles met the requirement, 9 articles discussed the result of therapy during the medication of COVID-19 patients, 2 reports of in vitro test, and 2 results of clinical trials. Conclusion: From several studies that had been conducted, remdesivir, combination of lopinavir and ritonavir, as well as favipiravir showed benefits in various clinical studies on Covid-19 patients. Meanwhile, chloroquine and hydroxychloroquine showed limited effects and did not affect the decrease of mortality.
References
[1] Rabby, M. I. I. (2020). Current drugs with potential for treatment of covid-19: A literature review. Journal of Pharmacy and Pharmaceutical Sciences, 23(1), 58–64.
[2] WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int/ (retrived on 9 October 2020).
[3] Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., Rajagopalan, K., Rahman, P. K. S. M., Cho, S. G., Kumar, N. S., & Subramaniam, M. D. (2020). COVID-19: A promising cure for the global panic. Science of the Total Environment, 725, 138277.
[4] Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Wang, C. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. New England Journal of Medicine, 382(19), 1787–1799.
[5] WHO. International Clinical Trials Registry Platform (ICTRP). Available online: https://www.who.int/ictrp/en/ (retrieved on 9 October 2020).
[6] Dehelean, C. A., Lazureanu, V., Coricovac, D., Mioc, M., Oancea, R., Marcovici, I., Pinzaru, I., Soica, C., Tsatsakis, A. M., & Cretu, O. (2020). SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. Journal of Clinical Medicine, 9(7), 1–40.
[7] Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020). Drug repurposing approach to fight COVID-19. Pharmacological Reports, 0123456789.
[8] IBM Micromedex Drug Ref. 2018. Copyright IBM Corporation, Version 2.5b851. United States.
[9] Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Liu, D., Clinical, D., Liu, D., Tan, W., Liu, D., & Clinical, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point?: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clinical Infectious Diseases, 2, 1–25.
[10] Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271.
[11] Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., … Wang, C. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. New England Journal of Medicine, 382(19), 1787–1799.
[12] Chen, C., Huang, J., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Zhang, J., Yin, P., & Wang, X. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv, 2020.03.17.20037432.
[13] Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the Treatment of Covid-19 — Preliminary Report. New England Journal of Medicine, 1–12.
[14] Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., … Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569–1578.
[15] Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., Chai, L. Y. A., Roestenberg, M., Tsang, O. T. Y., Bernasconi, E., Le Turnier, P., Chang, S. C., Sengupta, D., Hyland, R. H., Osinusi, A. O., … Marty, F. M. (2020). Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 324(11).
[16] Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., Chen, Y.-S., SenGupta, D., Hyland, R. H., Osinusi, A. O., Cao, H., Blair, C., Wei, X., Gaggar, A., Brainard, D. M., … Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 1–11.
[17] Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W. (2020). Observational study of hydroxychloroquine in hospitalized patients with COVID-19. New England Journal of Medicine, 382(25), 2411–2418.
[18] Skipper, C., Pastick,K., Engen, N. (2020). Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial. Annals of Internal Medicine.
[19] Mitja, O., Monne,M., Ubals,M., et al. (2020). Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized- Controlled Trial. Oxford University Press for the Infectious Diseases Society of America.
[20] Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Dee, D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., Mckinnon, J. E., Neill, W. O., Zervos, M., & Task, H. F. C.-. (2020). Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases. 97, 396–403
[21] Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., Dehovitz, J., Blog, D. S., Hutton, B., Holtgrave, D. R., & Zucker, H. A. (2020). Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. JAMA - Journal of the American Medical Association, 323(24), 2493–2502.
[22] Mckee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020). Candidate drugs against SARS-CoV-2 and COVID-19. Science Direct Pharmacological Research. 157 104859.
[23] IDSA. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Available online: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (retrieved on 9 October 2020)
[24] Ruamviboonsuk, P., Lai, T. Y. Y., Chang, A., Lai, C. C., Mieler, W. F., & Lam, D. S. C. (2020). Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.), 9(2), 85–87.
[25] Meyerowitz, E. A., Vannier, A. G. L., Friesen, M. G. N., Schoenfeld, S., Gelfand, J. A., Callahan, M. V., Kim, A. Y., Reeves, P. M., & Poznansky, M. C. (2020). Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB Journal, 34(5), 6027–6037.
[26] Van den Broek, M. P. H., Möhlmann, J. E., Abeln, B. G. S., Liebregts, M., van Dijk, V. F., & van de Garde, E. M. W. (2020). Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands Heart Journal, 28(7–8), 406–409.
[27] EMA. COVID-19: Chloroquine and Hydroxychloroquine Only to be Used in Clinical Trials or Emergency Use Programmes. Available online: https://www.ema.europa.eu/en/documents/press-release/covid19-chloroquine hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf (retrieved on 8 October 2020).
[28] WHO.Solidarity Clinical Trial for COVID-19 Treatments. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trialfor-covid-19-treatments (retrieved on 8 October 2020).
[29] IDSA. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-3
[30] Barlow, A., Landolf, K. M., Barlow, B., Yeung, S. Y. A., Heavner, J. J., Claassen, C. W., & Heavner, M. S. (2020). Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy, 40(5), 416–437.
[31] Gilead. (2020). Summary on compassionate use Remdesivir Gilead International Nonproprietary Name?: remdesivir. European Medicines Agency, 31(April), 41. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
